Renaissance Capital logo

MBX News

Endocrine biotech MBX Biosciences prices upsized IPO at $16, the high end of the range

MBX Biosciences logo

MBX Biosciences, a Phase 2 biotech developing precision peptides for endocrine and metabolic diseases, raised $163 million by offering 10.2 million shares at $16, the high end of the range of $14 to $16. The company upsized its offering by 1.7 million shares,...read more

Phase 2 precision peptide biotech MBX Biosciences sets terms for $128 million IPO

MBX Biosciences logo

MBX Biosciences, a Phase 2 biotech developing precision peptides for endocrine and metabolic diseases, announced terms for its IPO on Monday. The Carmel, IN-based company plans to raise $128 million by offering 8.5 million shares at a price range of $14 to $16....read more

US IPO Week Ahead: A trio of biotechs kick off fall IPO market

CBLL

Updated Monday 9/9/24 Three biotechs are scheduled to complete IPOs this week.   Bicara Therapeutics (BCAX) plans to raise $200 million at an $865 million market cap. Its lead candidate, ficerafusp alfa, is a bifunctional...read more

US IPO Weekly Recap: WeRide delays its IPO as pipeline gets a boost

WRD

Two small IPOs debuted this past week, while six IPOs submitted initial filings. Notably, China-based autonomous driving developer WeRide (WRD) postponed its $110 million US IPO. The company, which had already delayed its IPO earlier, stated...read more